IV

Invitae CorpFRA Invitae Stock Report

Last reporting period 30 Sep, 2023

Updated —

Last price

Market cap $B

0.005

Micro

Exchange

XFRA - Deutsche Boerse AG

IV8.F Stock Analysis

IV

Uncovered

Invitae Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-9/100

Low score

Market cap $B

0.005

Dividend yield

Shares outstanding

246.24 B

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. The company is headquartered in San Francisco, California and currently employs 1,700 full-time employees. The company went IPO on 2015-02-12. The firm is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. These tests are delivered through a platform that serves patients, healthcare providers, biopharma companies and other partners, thereby capturing the potential of genetics and helping to expand its use across the healthcare continuum. The company offers Invitae Digital Health, a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. The firm offers genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions, and rare diseases.

View Section: Eyestock Rating